Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cella

Showing results (241-250 of 1,016) with videos related to

Pageof 102
Sort By:
Journal of Clinical Epidemiology|March 3, 2016
Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behaviorRobert L Askew, Karon F Cook, Dennis A Revicki, et al.
Journal of Geriatric Oncology|September 15, 2021
Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemiaJohn Devin Peipert, Fabio Efficace, Renee Pierson, et al.
Journal of Pediatric Psychology|May 13, 2022
Psychometric Considerations in Developing PROMIS® Measures for Early ChildhoodJin-Shei Lai, Michael A Kallen, Courtney K Blackwell, et al.
Psycho-Oncology|March 8, 2007
Assessment is not enough: a randomized controlled trial of the effects of HRQL assessment on quality of life and satisfaction in oncology clinical practiceSarah K Rosenbloom, David E Victorson, Elizabeth A Hahn, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 23, 2009
Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global itemsRon D Hays, Jakob B Bjorner, Dennis A Revicki, et al.
Breast Cancer Research and Treatment|January 25, 2007
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trialGershon Y Locker, Robert Mansel, David Cella, et al.
Medical Care|August 23, 2007
Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5DA Simon Pickard, Thomas Kohlmann, Mathieu F Janssen, et al.
Journal of Pain and Symptom Management|January 29, 2003
Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scalesDavid Cella, David T Eton, Jin-Shei Lai, et al.
Cancer Journal (Sudbury, Mass.)|June 21, 2002
Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296Scott Wadler, Carlos Brain, Paul Catalano, et al.
Journal of Patient-Reported Outcomes|February 9, 2019
Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findingsNina Galipeau, Brittany Klooster, Meaghan Krohe, et al.
Pageof 102

Showing results (241-250 of 1,016) with videos related to

Sort By:
Pageof 102
Journal of Clinical Epidemiology|March 3, 2016
Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behaviorRobert L Askew, Karon F Cook, Dennis A Revicki, et al.
Journal of Geriatric Oncology|September 15, 2021
Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemiaJohn Devin Peipert, Fabio Efficace, Renee Pierson, et al.
Journal of Pediatric Psychology|May 13, 2022
Psychometric Considerations in Developing PROMIS® Measures for Early ChildhoodJin-Shei Lai, Michael A Kallen, Courtney K Blackwell, et al.
Psycho-Oncology|March 8, 2007
Assessment is not enough: a randomized controlled trial of the effects of HRQL assessment on quality of life and satisfaction in oncology clinical practiceSarah K Rosenbloom, David E Victorson, Elizabeth A Hahn, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|June 23, 2009
Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global itemsRon D Hays, Jakob B Bjorner, Dennis A Revicki, et al.
Breast Cancer Research and Treatment|January 25, 2007
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trialGershon Y Locker, Robert Mansel, David Cella, et al.
Medical Care|August 23, 2007
Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5DA Simon Pickard, Thomas Kohlmann, Mathieu F Janssen, et al.
Journal of Pain and Symptom Management|January 29, 2003
Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scalesDavid Cella, David T Eton, Jin-Shei Lai, et al.
Cancer Journal (Sudbury, Mass.)|June 21, 2002
Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296Scott Wadler, Carlos Brain, Paul Catalano, et al.
Journal of Patient-Reported Outcomes|February 9, 2019
Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findingsNina Galipeau, Brittany Klooster, Meaghan Krohe, et al.
Pageof 102